Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 201–300 of 1,002
Transgenic mouse models of Alzheimer's disease
Janus, C., & Westaway, D. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00524-8 · Cited by 176
Self-citationAmyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S., & Beisiegel, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00458-5 · Cited by 180
Metallothionein III is reduced in Alzheimer’s disease
Yu, W. H., Lukiw, W. J., Bergeron, C., Niznik, H. B., & Fraser, P. E. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03196-6 · Cited by 179
Self-citationThe γ-secretase complex: from structure to function
Zhang, X., Li, Y., Xu, H., & Zhang, Y.-W. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00427 · Cited by 160
“directly linked to APP processing and are all seen to increase the relative abundance of the more aggregation-prone Aβ42 compared to Aβ40 (Borchelt et al., 1996, 1997; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Siman et al., 2000; Flood et al., 2002; Haass et al., 2012).”
BackgroundBiogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
Weidemann, A., Paliga, K., Dürrwang, U., Reinhard, F. B. M., Schuckert, O., Evin, G., & Masters, C. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5823 · Cited by 172
γ-Secretase Mutations in Hidradenitis Suppurativa: New Insights into Disease Pathogenesis
Pink, A. E., Simpson, M. A., Desai, N., Trembath, R. C., & Barker, J. N. W. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.372 · Cited by 170
“, 1999) but increase the length of b-amyloid peptides produced following the cleavage of amyloid precursor protein (APP; b-amyloid deposition forms the cerebral plaques in FAD; Duff et al., 1996; Citron et al., 1997).”
BackgroundBORCHARDT, T., CAMAKARIS, J., CAPPAI, R., MASTERS, C. L., BEYREUTHER, K., & MULTHAUP, G. (1999) · Biochemical Journal · doi:10.1042/bj3440461 · Cited by 171
Aβ42-Peptide Assembly on Lipid Bilayers
Yip, C. M., Darabie, A. A., & McLaurin, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00028-1 · Cited by 177
Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J., & Selkoe, D. J. (1998) · Biochemistry · doi:10.1021/bi9816195 · Cited by 169
Self-citationGiannakopoulos, P., Hof, P. R., Michel, J.-P., Guimon, J., & Bouras, C. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00023-4 · Cited by 175
Stable Association of Presenilin Derivatives and Absence of Presenilin Interactions with APP
Thinakaran, G., Regard, J. B., Bouton, C. M. L., Harris, C. L., Price, D. L., Borchelt, D. R., & Sisodia, S. S. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0171 · Cited by 175
“…of highly amyloidogenic, 42- to 43-aminoacid b-amyloid peptides (Ab42) (Scheuner et al., 1996; Duff et al., 1996; Borchelt et al., 1996; Citron et al., 1997; Tomita et al., 1997), which are deposited early and selectively in AD brain (Gravina et al., 1995; Iwatsubo et al., 1994; Lemere…”
BackgroundQian, S., Jiang, P., Guan, X.-M., Singh, G., Trumbauer, M. E., Yu, H., Chen, H. Y., Van der Ploeg, L. H. T., & Zheng, H. (1998) · Neuron · doi:10.1016/s0896-6273(00)80999-x · Cited by 169
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 169
Gandhi, J., Antonelli, A. C., Afridi, A., Vatsia, S., Joshi, G., Romanov, V., Murray, I. V. J., & Khan, S. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0035 · Cited by 164
Autophagy, polyphenols and healthy ageing
Pallauf, K., & Rimbach, G. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.03.008 · Cited by 164
Genetics of Alzheimer's Disease
Guerreiro, R., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 155
Morohashi, Y., Hatano, N., Ohya, S., Takikawa, R., Watabiki, T., Takasugi, N., Imaizumi, Y., Tomita, T., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200897200 · Cited by 164
Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., & Holtzman, D. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07889.2003 · Cited by 160
“Interestingly, many of the mutations that result in familial AD appear to result from an increase in production of A 42 , a particularly amyloidogenic form of A (Citron et al., 1992, 1997; Cai et al., 1993; Haass et al., 1994; Borchelt et al., 1996, 1997; Eckman et al., 1997).”
BackgroundZou, K., Kim, D., Kakio, A., Byun, K., Gong, J., Kim, J., Kim, M., Sawamura, N., Nishimoto, S., Matsuzaki, K., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02018.x · Cited by 155
“Familial-AD-linked mutations of b-amyloid precursor protein (APP) and presenilins increase the relative concentration of Ab1–42 (Suzuki et al. 1994; Borchelt et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Eckman et al. 1997; Tomita et al. 1997).”
BackgroundPresenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
Presenilin-1 mutations in Alzheimer's disease
Russo, C., Schettini, G., Saido, T. C., Hulette, C., Lippa, C., Lannfelt, L., Ghetti, B., Gambetti, P., Tabaton, M., & Teller, J. K. (2000) · Nature · doi:10.1038/35014735 · Cited by 158
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
“Similarly, expression of mutant, but not wild-type, human PS1 in transgenic mice increases the brain concentrations of A β1–42 encoded by the endogenous mouse App gene ( 19) or by mutant ( 20) or wild-type (21) human APP transgenes.”
BackgroundSelf-citationBegley, J. G., Duan, W., Chan, S., Duff, K., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721030.x · Cited by 158
“Presenilin mutations have been shown to alter APP processing (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997), but the relationship of such alterations to perturbed calcium homeostasis and increased neuronal vulnerability to apoptosis is unclear.”
BackgroundTheFEAR: a rapid screening instrument for generalized anxiety in elderly primary care attenders
Krasucki, C., Ryan, P., Ertan, T., Howard, R., Lindesay, J., & Mann, A. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199901)14:1<60::aid-gps893>3.0.co;2-g · Cited by 54
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 183
Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 148
“It is plausible that this is because of the increased production of Ab42 compared to Ab40 in brains with the PSEN1 mutation, as observed by other laboratories (Borchelt et al. 1996; Citron et al. 1997; Shimojo et al. 2008).”
ResultRogaeva, E. A., Premkumar, S., Song, Y., Sorbi, S., Brindle, N., Paterson, A., Duara, R., Levesque, G., Yu, G., Nishimura, M., et al. (1998) · JAMA · doi:10.1001/jama.280.7.614 · Cited by 160
Evidence for a Six-transmembrane Domain Structure of Presenilin 1
Lehmann, S., Chiesa, R., & Harris, D. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.12047 · Cited by 152
Mouri, A., Noda, Y., Hara, H., Mizoguchi, H., Tabira, T., & Nabeshima, T. (2007) · The FASEB Journal · doi:10.1096/fj.06-7685com · Cited by 142
Genomics of Alzheimer Disease: A Review
Rosenberg, R. N., Lambracht-Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 146
Self-citationMolecular genetics of Alzheimer's disease
Cruts, M., & vanBroeckhoven, C. (1998) · Annals of Medicine · doi:10.3109/07853899809002605 · Cited by 148
Presenilin function and γ‐secretase activity
Brunkan, A. L., & Goate, A. M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03099.x · Cited by 145
“Transgenic mice that express mutant PS transgenes display elevated brain Ab levels but do not develop neuritic plaques (Duff et al. 1996; Borchelt et al. 1997; Citron et al. 1997; Oyama et al. 1998; Siman et al. 2000).”
BackgroundThe Genetics of Adult-Onset Neuropsychiatric Disease: Complexities and Conundra?
Kennedy, J. L., Farrer, L. A., Andreasen, N. C., Mayeux, R., & St George-Hyslop, P. (2003) · Science · doi:10.1126/science.1092132 · Cited by 150
A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease
Salek, R. M., Xia, J., Innes, A. E., Sweatman, B. C., Adalbert, R., Randle, S. J., McGowan, E. M., Emson, P. C., & Griffin, J. L. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.04.001 · Cited by 156
“Despite formation of age-dependent amyloid pathology none of these transgenic mice developed widespread neuronal loss (Citron et al., 1997; Irizarry et al., 1997) nor marked neurofibrillary tangle pathology, although several of these models have tau positive dystrophic neurites (see reviews by…”
BackgroundSecretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 146
Abnormal Glutamate Transport Function in Mutant Amyloid Precursor Protein Transgenic Mice
Masliah, E., Alford, M. F., Mallory, M. E., Rockenstein, E. M., Moechars, D., & LEUVEN, F. V. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7386 · Cited by 148
Hyperaccumulation of FAD-linked presenilin 1 variants in vivo
Lee, M. K., Borchelt, D., Kim, G. J., Thinakaran, G., Slunt, H. H., Ratovitski, T., Martin, L. J., Kittur, A., Gandy, S., Levey, A. I., et al. (1997) · Nature Medicine · doi:10.1038/nm0797-756 · Cited by 157
Self-citationPresenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch
Capell, A., Steiner, H., Romig, H., Keck, S., Baader, M., Grim, M. G., Baumeister, R., & Haass, C. (2000) · Nature Cell Biology · doi:10.1038/35008626 · Cited by 166
Kalback, W. M., Watson, M. D., Kokjohn, T. A., Kuo, Y., Weiss, N., Luehrs, D. C., Lopez, J. C., Brune, D. C., Sisodia, S. S., Staufenbiel, M., et al. (2001) · Biochemistry · doi:10.1021/bi015685+ · Cited by 175
Chromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease
Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 157
D'Andrea, M., & Nagele, R. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775474224 · Cited by 146
Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration
Eriksen, J. L., & Janus, C. G. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9118-z · Cited by 146
Inflammatory aspects of Alzheimer’s disease
Lucena, P. B., & Heneka, M. T. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02790-2 · Cited by 164
“EOAD mutations in APP and PS1/2 alter Aβ biogenesis, resulting in an altered formation of amyloidogenic Aβ peptides [43, 52, 91, 152, 172, 240, 249].”
Cyclin‐dependent kinase‐5 in neurodegeneration
Shelton, S. B., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02328.x · Cited by 158
“Presenilin-1 mutations are associated with marked increases in Ab1)42 production and early onset familial Alzheimer’s disease (Citron et al. 1997).”
BackgroundHaass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“What about the much more common AD-causing mutations in the homologous presenilin-1 (PS1) and presenilin-2 (PS2) genes? Strikingly, all these mutations increase the relative levels of the longer Aβ42 and Aβ43 species, similar to the carboxyl-terminal APP mutations (Fig 1A) [24,25].”
BackgroundSelf-citationInhibition and Modulation of γ-Secretase for Alzheimer's Disease
Wolfe, M. S. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.010 · Cited by 143
Presenilins: Genes for Life and Death
Haass, C. (1997) · Neuron · doi:10.1016/s0896-6273(00)80309-8 · Cited by 145
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
Menting, K. W., & Claassen, J. A. H. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00165 · Cited by 171
“…www.frontiersin.org July 2014 | Volume 6 | Article 165 | 1 for presenilin proteins which are subcomponents of γ-secretase, and ApoE-ε4, an isoform of lipoprotein which is less efficient in catalyzing the breakdown of Aβ compared to other isoforms (Citron et al., 1992, 1997; Schmechel et al., 1993).”
BackgroundTargeting the JAK2/STAT3 axis in Alzheimer's disease
Chiba, T., Yamada, M., & Aiso, S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903213426 · Cited by 147
“Amyloid β (Aβ), the main component of senile plaques, has long been implicated in the pathogenesis of AD because elevated levels of toxic longer forms of Aβ have been invariably found in a number of AD models based on the FAD genes in vitro and in vivo [4-6].”
BackgroundPresenilins: molecular switches between proteolysis and signal transduction
Annaert, W. G., & Strooper, B. D. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01455-1 · Cited by 158
Alzheimer’s disease and Notch signaling
Woo, H., Park, J. S., Gwon, A., Arumugam, T. V., & Jo, D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.093 · Cited by 148
Barelli, H., Lebeau, A., Vizzavona, J., Delaère, P., Chevallier, N., Drouot, C., Marambaud, P., Ancolio, K., Buxbaum, J. D., Khorkova, O., et al. (1997) · Molecular Medicine · doi:10.1007/bf03401708 · Cited by 149
“The gene products, presenilins 1 and 2, likely interfere with 13APP processing since pathological mutations in presenilins trigger increased A1342 over A340 ratios (18-20).”
BackgroundSubcellular Distribution and Turnover of Presenilins in Transfected Cells
Zhang, J., Kang, D. E., Xia, W., Okochi, M., Mori, H., Selkoe, D. J., & Koo, E. H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12436 · Cited by 146
Self-citationAmyloid-β in Alzheimer Disease: The Null versus the Alternate Hypotheses
Lee, H., Zhu, X., Castellani, R. J., Nunomura, A., Perry, G. L., & Smith, M. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114009 · Cited by 157
“Most importantly however, missense mutations in the presenilin genes increase the ratio of A 1–42/A 1–40 (Citron et al., 1997; Tomita et al., 1997).”
BackgroundMarchetti, C., & Marie, H. (2011) · revneuro · doi:10.1515/rns.2011.035 · Cited by 136
Phosphatidylinositol and inositol involvement in alzheimer amyloid-β fibril growth and arrest
McLaurin, J., Franklin, T., Chakrabartty, A., & Fraser, P. E. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1677 · Cited by 161
Self-citationChaudhury, A. R., Gerecke, K. M., Wyss, J. M., Morgan, D. G., Gordon, M. N., & Carroll, S. L. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.1.42 · Cited by 138
Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease
Pugh, P. L., Richardson, J. C., Bate, S. T., Upton, N., & Sunter, D. C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.11.044 · Cited by 152
“[7] Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al.”
Alzheimer’s Disease as Proteolytic Disorders: Anabolism and Catabolism of β-Amyloid
Saido, T. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00033-5 · Cited by 154
Single and multiple transgenic mice as models for Alzheimer's disease
LEUVEN, F. V. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00055-6 · Cited by 145
Hartmann, D., Strooper, B. D., & Säftig, P. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80331-5 · Cited by 151
“Missense mutations of the human PS1 gene are a major cause of familial Alzheimer’s disease [4], leading to an increased production of the long, strongly amyloidogenic form of the β-A4 amyloid peptide from the amyloid precursor protein (APP) [9–12].”
γ‐Secretase inhibitors and modulators for Alzheimer’s disease
Wolfe, M. S. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07501.x · Cited by 134
Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors
Guglielmotto, M. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2010 · Cited by 159
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 133
Houlden, H., Baker, M., McGowan, E., Lewis, P., Hutton, M., Crook, R., Wood, N. W., Kumar-Singh, S., Geddes, J., Swash, M., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<806::aid-ana18>3.0.co;2-f · Cited by 135
Mills, J., Laurent Charest, D., Lam, F., Beyreuther, K., Ida, N., Pelech, S. L., & Reiner, P. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09415.1997 · Cited by 134
“…presenilin-1, another protein thought to alter APP processing via its effects on protein trafficking (Borchelt et al., 1996; Lemere et al., 1996; Citron et al., 1997; Weidemann et al., 1997), has a consensus sequence for ERK-dependent phosphorylation and has been shown recently to be a…”
BackgroundThe Role of Presenilins in γ-Secretase Activity
Wolfe, M. S., & Haass, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000026200 · Cited by 132
Making the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
“They affect the cleavage of γ-secretase such that increased amounts of the pathogenic Aβ42 relative to Aβ40 are generated [14-16].”
BackgroundSiman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y.-G., Scott, R. W., & Flood, D. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08717.2000 · Cited by 133
“This is similar to the Ab42/Ab40 secretion ratios reported previously for numerous cultured cell lines under nonkinetic conditions (Suzuki et al., 1994; Scheuner et al., 1996; Citron et al., 1997).”
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehuette, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 131
“] and the history given by the relatives. Laboratory investigations, including magnetic resonance imaging and/or computerized tomography were carried out in all PD and PDD patients to exclude other reasons for cognitive decline. All routine CSF parameters (protein content, white and red blood cell count) were normal.…”
MethodProtein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms
Forloni, G., Terreni, L., Bertani, I., Fogliarino, S., Invernizzi, R. W., Assini, A., Ribizzi, G., Negro, A., Calabrese, E., Volonté, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00076-3 · Cited by 147
FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction
Flood, D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00330-x · Cited by 131
Steiner, H., Romig, H., Grim, M. G., Philipp, U., Pesold, B., Citron, M., Baumeister, R., & Haass, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7615 · Cited by 127
Self-citationDavis, J. A., Naruse, S., Chen, H., Eckman, C., Younkin, S. G., Price, D. L., Borchelt, D., Sisodia, S. S., & Wong, P. C. (1998) · Neuron · doi:10.1016/s0896-6273(00)80998-8 · Cited by 141
Leimer, U., Lun, K., Romig, H., Walter, J., Grünberg, J., Brand, M., & Haass, C. (1999) · Biochemistry · doi:10.1021/bi991453n · Cited by 129
Murayama, O., Tomita, T., Nihonmatsu, N., Murayama, M., Sun, X., Honda, T., Iwatsubo, T., & Takashima, A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00187-1 · Cited by 147
Alzheimer disease: Amyloidogenesis, the presenilins and animal models
Newman, M., Musgrave, I., & Lardelli, M. T. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.12.001 · Cited by 157
“peptides [58-60] and there is a reduction in γ-secretase cleavage of APP in neuronal cultures derived from PS1 deficient mice embryos [61].”
BackgroundCollins, J. S., Perry, R. T., Watson, B., Harrell, L. E., Acton, R. T., Blacker, D., Albert, M. S., Tanzi, R. E., Bassett, S. S., McInnis, M. G., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001204)96:6<823::aid-ajmg26>3.0.co;2-i · Cited by 129
“…1992], and presenillin 2 (PS2) on chromosome 1 [Levy-Lahad et al., 1995], are proposed to cause AD by increasing the production of Ab42 [Scheuner et al., 1996; Selkoe, 1996; Citron et al., 1997], which aggregates [Jarrett and Lansbury, 1993] to form neurotoxic AD plaques [Yankner et al., 1989].”
BackgroundNicastrin binds to membrane-tethered Notch
Chen, F., Yu, G., Arawaka, S., Nishimura, M., Kawarai, T., Yu, W. H., Tandon, A., Supala, A., Song, Y., Rogaeva, E. A., et al. (2001) · Nature Cell Biology · doi:10.1038/35087069 · Cited by 141
Self-citationGenetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
Walton, J. R. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132204 · Cited by 123
“Secondly, A 42 levels are increased in AD brain tissue by mutant presenilins [358].”
BackgroundThe Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 122
“The mutations increase the ratio of Aβ42 to Aβ40, which may result from reduced γ-secretase activity (Citron et al., 1997). sAD: ApoE, BIN1 and TREM2 Most cases of AD are sporadic.”
BackgroundButterfield, D. A., & Sultana, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12107 · Cited by 126
Does my mouse have Alzheimer's disease?
Dodart, J. ‐., Mathis, C., Bales, K. R., & Paul, S. M. (2002) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2002.10302.x · Cited by 129
“By contrast, tg mice expressing either a wt or mutated PS gene fail to develop significant ADlike pathology, despite the fact that mutant PS tg mice have higher levels of brain Ab (Borchelt et al. 1996; Duff et al. 1996; Citron et al. 1997; Oyama et al. 1998; Chui et al. 1999).”
BackgroundStructure and Function of the γ-Secretase Complex
Wolfe, M. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00401 · Cited by 116
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 101
“�inding the remaining genetic factors that contribute to the development of late onset Alzheimer’s disease holds the potential to provide novel targets for treatment and prevention, leading to the development of effective strategies to combat this devastating disease.”
BackgroundAccumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice
Ikeda, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., Sasaki, A., Tomidokoro, Y., Ikarashi, Y., Kuribara, H., Ishiguro, K., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62274-2 · Cited by 120
Self-citationIntracellular amyloid and the neuronal origin of Alzheimer neuritic plaques
Pensalfini, A., Albay, R., Rasool, S., Wu, J. W., Hatami, A., Arai, H., Margol, L., Milton, S., Poon, W. W., Corrada, M. M., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.011 · Cited by 120
Wolfe, M. S. (2009) · Chemical Reviews · doi:10.1021/cr8004197 · Cited by 132
Biomarkers of neurodegenerative disorders: How good are they?
Rachakonda, V., Pan, T. H., & Le, W. D. (2004) · Cell Research · doi:10.1038/sj.cr.7290235 · Cited by 134
Migliore, L., Botto, N., Scarpato, R., Petrozzi, L., Cipriani, G., & Bonuccelli, U. (1999) · Cytogenetic and Genome Research · doi:10.1159/000015389 · Cited by 119
“…hypotheses are being tested in various laboratories, using a wide range of methodologies, including studies with mice trans- 42 Cytogenet Cell Genet 87:41–46 (1999) genic for wild-type or mutated APP and presenilin genes (Bales et al., 1997; Citron et al., 1997; Sturchler-Pierrat et al., 1997).”
MethodQuintero-Monzon, O., Martin, M. M., Fernandez, M. A., Cappello, C. A., Krzysiak, A. J., Osenkowski, P., & Wolfe, M. S. (2011) · Biochemistry · doi:10.1021/bi2007146 · Cited by 118
Pujol‐Pina, R., Vilaprinyó-Pascual, S., Mazzucato, R., Arcella, A., Vilaseca, M., Orozco, M., & Carulla, N. (2015) · Scientific Reports · doi:10.1038/srep14809 · Cited by 117
Amyloid-β Production: Major Link Between Oxidative Stress and BACE1
Tamagno, E., Guglielmotto, M., Monteleone, D., & Tabaton, M. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9283-6 · Cited by 125
“Ab42, increasing its production and accumulation (Citron et al. 1992; Citron et al. 1997; Lemere et al.1996).”
Developmental expression of p-glycoprotein (multidrug resistance gene product) in the rat brain
Matsuoka, Y., Okazaki, M., Kitamura, Y., & Taniguchi, T. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(19990605)39:3<383::aid-neu5>3.0.co;2-4 · Cited by 107
Sjögren, M., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, Å., Vanmechelen, E., Wallin, A., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051268 · Cited by 122
Parent, A., Linden, D. J., Sisodia, S. S., & Borchelt, D. R. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0207 · Cited by 116
Synaptic Dysfunction in Alzheimer’s Disease
Marcello, E. E., Epis, R., Saraceno, C., & Luca, M. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_25 · Cited by 125
“In addition to the cloning of PS1 and PS2 and the discovery that they alter APP metabolism (Borchelt et al. 1996; Duff et al. 1996; Citron et al. 1997) through a direct effect on the g-secretase protease (De Strooper et al.”
BackgroundKoch, P., Tamboli, I. Y., Mertens, J., Wunderlich, P., Ladewig, J., Stüber, K., Esselmann, H., Wiltfang, J., Brüstle, O., & Walter, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.012 · Cited by 129
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.